Skip to main content
    V

    Viridian Therapeutics Inc (VRDN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.80
    -1.07 (-3.47%)

    Market Cap: $3.51B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Viridian Therapeutics Inc (VRDN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Viridian Therapeutics (VRDN) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Viridian Therapeutics reported EPS of -$0.81, above the -$1.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -10.90%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.72
    Range-$0.83 - -$0.61
    16 analysts
    Revenue Consensus
    $50.04M
    Range$30.29M - $74.87M
    16 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.75
    Range-$0.95 - -$0.53
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.89+15.7%
    60d ago-$0.89+15.7%
    30d ago-$0.89+15.7%
    7d ago-$0.88+14.7%
    Current-$0.75
    Revenue Consensus
    $67.96M
    Range$53.00M - $82.81M
    4 analysts

    Next Report

    VRDN has an expected report date of Feb 24, 2027.

    VRDN Earnings Call

    The latest VRDN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, VRDN beat 19, missed 18 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $25.75M, down 63.5% from $70.57M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.81-$1.01-$1.26 - -$0.78+19.80%BeatN/A121 up, 0 downNov 4, 2026$25.75M
    Jun 30, 2026-$1.05-$0.97-$1.22 - -$0.87-8.25%MissN/A113 up, 2 downAug 6, 2026$284000
    Mar 31, 2026-$0.90-$1.08-$1.29 - -$0.94+16.67%BeatN/A110 up, 1 downMay 5, 2026$141000
    Dec 31, 2025-$1.08-$0.90-$1.32 - -$0.59-20.00%MissN/A120 up, 2 downFeb 26, 2026$132000
    Sep 30, 2025-$0.34-$0.82-$1.30 - -$0.27+58.54%BeatN/A101 up, 3 downNov 5, 2025$70.57M
    Jun 30, 2025-$1.00-$0.98-$1.09 - -$0.81-2.04%MissN/A123 up, 5 downAug 6, 2025$75000
    Mar 31, 2025-$0.87-$0.96-$1.28 - -$0.84+9.38%BeatN/A93 up, 1 downMay 6, 2025$72000
    Dec 31, 2024-$0.81-$1.04-$1.20 - -$0.84+22.43%BeatN/A121 up, 6 downFeb 27, 2025$72000
    Sep 30, 2024-$1.15-$1.05-$1.17 - -$0.80-9.52%MissN/A140 up, 0 downNov 12, 2024$86000
    Jun 30, 2024-$1.02-$0.92-$1.14 - -$0.69-10.87%MissN/A150 up, 0 downAug 8, 2024$72000
    Mar 31, 2024-$0.79-$1.10-$1.36 - -$0.81+28.18%BeatN/A120 up, 0 downMay 8, 2024$72000
    Dec 31, 2023-$1.35-$1.03-$1.17 - -$0.84-31.07%MissN/A130 up, 0 downFeb 27, 2024$72000
    Sep 30, 2023-$1.09-$1.24-$1.44 - -$0.91+12.10%BeatN/A140 up, 0 downNov 13, 2023$72000
    Jun 30, 2023-$1.27-$1.26-$1.69 - -$0.97-0.79%MissN/A141 up, 0 downAug 8, 2023$72000
    Mar 31, 2023-$1.61-$1.02-$1.23 - -$0.82-57.84%MissN/A100 up, 0 downMay 9, 2023$98000
    Dec 31, 2022-$1.13-$0.72-$0.94 - -$0.50-56.94%MissN/A100 up, 0 downMar 8, 2023$105000
    Sep 30, 2022-$0.86-$1.01-$1.24 - -$0.48+14.85%BeatN/A80 up, 0 downNov 14, 2022$1.20M
    Jun 30, 2022-$1.06-$0.90-$1.05 - -$0.51-17.78%MissN/A70 up, 0 downAug 15, 2022$256000
    Mar 31, 2022-$0.98-$1.08-$1.32 - -$0.90+9.26%BeatN/A50 up, 0 downMay 12, 2022$216000
    Dec 31, 2021-$1.32-$0.99-$1.43 - -$0.33-33.33%MissN/A70 up, 0 downMar 10, 2022$214000
    Sep 30, 2021-$1.25-$1.34-$2.29 - -$0.26+6.72%BeatN/A6N/ANov 4, 2021$208000
    Jun 30, 2021-$2.21-$1.40-$2.65 - -$0.32-57.86%MissN/A5N/AAug 11, 2021$1.09M
    Mar 31, 2021-$2.91-$0.76-$1.65 - -$0.30-282.89%MissN/A5N/AMay 6, 2021$1.45M
    Dec 31, 2020-$30.74-$1.03-$1.27 - -$0.19N/AN/AN/A3N/AMar 25, 2021$54000
    Sep 30, 2020-$1.50-$1.99N/A+24.62%BeatN/AN/AN/ANov 10, 2020N/A
    Jun 30, 2020-$1.80-$2.47N/A+27.13%BeatN/AN/AN/AAug 5, 2020$168000
    Mar 31, 2020-$2.70-$2.88N/A+6.25%BeatN/AN/AN/AMay 7, 2020$828000
    Dec 31, 2019-$4.65-$3.78N/A-23.02%MissN/AN/AN/AMar 11, 2020$880000
    Sep 30, 2019-$5.40-$4.44N/A-21.62%MissN/AN/AN/ANov 7, 2019$695000
    Jun 30, 2019-$4.35-$5.45N/A+20.18%BeatN/AN/AN/AAug 7, 2019$2.51M
    Mar 31, 2019-$5.70-$5.16N/A-10.47%MissN/AN/AN/AMay 8, 2019$372000
    Dec 31, 2018-$4.95-$4.62N/A-7.14%MissN/AN/AN/AMar 13, 2019$476000
    Sep 30, 2018-$4.35-$4.76N/A+8.61%BeatN/AN/AN/ANov 7, 2018$944000
    Jun 30, 2018-$4.35-$4.35N/A0.00%In lineN/AN/AN/AAug 7, 2018$2.18M
    Mar 31, 2018-$2.70-$3.67N/A+26.43%BeatN/AN/AN/AMay 9, 2018$4.78M
    Dec 31, 2017-$4.35-$4.76N/A+8.61%BeatN/AN/AN/AMar 14, 2018$1.19M
    Sep 30, 2017-$4.05-$5.70N/A+28.95%BeatN/AN/AN/ANov 8, 2017$1.63M
    Jun 30, 2017-$5.10-$7.05N/A+27.66%BeatN/AN/AN/AAug 11, 2017$718000
    Mar 31, 2017-$9.00-$3.60N/A-150.00%MissN/AN/AN/AMay 10, 2017$462000
    Dec 31, 2016-$3.45-$3.45N/A0.00%In lineN/AN/AN/AMar 24, 2017$756000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.29, after -$3.77 the year before. It was -$117.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.29N/A
    Dec 31, 2024-$3.77N/A
    Dec 31, 2023-$5.32N/A
    Dec 31, 2022-$4.03N/A
    Dec 31, 2021-$7.69N/A
    Dec 31, 2020-$36.74N/A
    Dec 31, 2019-$20.10N/A
    Dec 31, 2018-$16.35N/A
    Dec 31, 2017-$22.50N/A
    Dec 31, 2016-$117.15N/A

    Earnings Calls

    The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 6,100 words across 21 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,10221

    2026Q3 Earnings Call

    Opening remarks

    Greg Rossino Senior Director of Investor Relations Thank you, Operator, and good morning, everyone. Thank you for joining us to discuss Viridian's third quarter 2026 financial results and recent business updates. You can access the press release and the slides for today's call on the Investors page of our corporate website at viridiantherapeutics.com. Before we begin, I would like to remind everyone that today's call and webcast will contain forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. A description of these risks can be found in the forward-looking statement section disclaimer in the press release and slides issued today, as well as our SEC filings, including our quarterly report on Form 10-Q. With me today are Steve Mahoney, our President and Chief Executive Officer, Tony Casciano, our Chief Commercial Officer, and Seth Harmon, our Chief Financial Officer. Shan Wu, our Chief Business Officer, will join us for Q&A. With that, I will turn the call over to Steve.

    Steve Mahoney President and Chief Executive Officer Thanks, Greg, and good morning, everyone. Thank you for joining us to discuss the results from our first quarter of Lumvoa launch in thyroid eye disease. As spelled out in our earnings release earlier this morning, it has been a very strong start, and the Viridian team has done another excellent job executing across the board. Lumvoa generated $24.7 million in net product revenue, and we had more than 100 patients on therapy as of September 30th. This is a very encouraging start to the launch and certainly has exceeded expectations. It is still early in the launch cycle, but we believe these results are a testament to Lumvoa's compelling product profile and the readiness and execution of our entire organization since day one of launch. Before we provide more color on the Lumvoa launch, I want to highlight the emerging Viridian pipeline, which we believe will drive the next chapter of Viridian's growth in autoimmune disease. First, we're on track to submit our BLA for elegrobart in the first quarter of 2027. Ellie is our next-generation subcutaneous anti-IGF-1R. Based on our phase III results, Ellie has the potential to further improve the TED patient experience, and we believe that it will encourage more patients to seek treatment with at-home self-administration as infrequently as every eight weeks. Later this quarter, we also look forward to sharing first-in-human results for VRDN-008. 008 is a half-life-extended FcRn inhibitor and is another example of a product candidate designed to reduce treatment burden with less frequent dosing while also providing sustained disease control. We're also making strong progress with our anti-TSHR product candidate, now called VRDN-292, which we believe has the potential to be best in class.

    Frequently Asked Questions About VRDN

    When is Viridian Therapeutics's next earnings date?

    Viridian Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did VRDN beat earnings estimates last quarter?

    Yes. Viridian Therapeutics reported EPS of -$0.81 for the quarter ended Sep 30, 2026, above the -$1.01 estimate, a 19.80% surprise.

    What EPS do analysts expect from VRDN next quarter?

    The consensus EPS estimate for Viridian Therapeutics for the quarter ending Dec 31, 2026 is -$0.72 from 16 analysts, with estimates from -$0.83 to -$0.61.

    How often does VRDN beat earnings estimates?

    Viridian Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +12.07%.